CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
We are very excited to launch our new website! Please take a few moments to click around and explore...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...